HC Wainwright Reaffirms “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $36.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 300.89% from the stock’s previous close.

Several other analysts also recently commented on FDMT. Barclays began coverage on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Chardan Capital reiterated a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Finally, Royal Bank Of Canada boosted their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $32.71.

4D Molecular Therapeutics Stock Up 4.9%

FDMT stock opened at $8.98 on Friday. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34. The firm has a market cap of $513.03 million, a PE ratio of -3.71 and a beta of 2.99. The business has a 50 day moving average of $8.73 and a 200 day moving average of $9.08.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Wednesday, March 18th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of ($0.53) by $0.96. The business had revenue of $85.09 million for the quarter, compared to the consensus estimate of $30.86 million. 4D Molecular Therapeutics had a negative return on equity of 33.37% and a negative net margin of 164.43%. On average, research analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors have recently made changes to their positions in FDMT. Dynamic Technology Lab Private Ltd bought a new stake in shares of 4D Molecular Therapeutics in the first quarter worth approximately $39,000. Wexford Capital LP bought a new position in 4D Molecular Therapeutics during the third quarter valued at approximately $41,000. Quadrature Capital Ltd purchased a new stake in 4D Molecular Therapeutics in the second quarter worth approximately $42,000. Farther Finance Advisors LLC boosted its holdings in 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after purchasing an additional 2,674 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in 4D Molecular Therapeutics in the 1st quarter worth approximately $46,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.